Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes - PubMed (original) (raw)
Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes
Michael A Perricone et al. J Immunother. 2004 Jul-Aug.
Abstract
Provoking a specific cellular immune response against tumor-associated antigens is a promising therapeutic strategy to treat cancers with defined antigens such as melanoma. In recent clinical trials, however, immune responses against melanoma antigens have been elicited without consistent clinical responses, suggesting the need for approaches that potentiate the specific cellular immune response. Since B lymphocytes have been reported to exert a negative effect on the cellular arm of the immune response in certain model systems, the authors compared the protective immunity elicited by melanoma antigens in B cell-deficient microMT mice to that obtained in fully immunocompetent C57BL/6 mice. Immunization with melanoma-associated antigens was accomplished using recombinant adenovirus (Ad) vectors encoding human gp100 (Ad2/gp100) or murine TRP-2 (Ad2/mTRP-2). A single dose of Ad2/gp100 or Ad2/mTRP-2 inhibited the growth of established subcutaneous B16 melanoma tumors in B cell-deficient but not wild-type C57BL/6 mice. The enhanced tumor protection observed in B cell-deficient mice appeared to be associated with potentiation of the magnitude and longevity of the specific cellular immune response. Natural killer (NK) cells were also found to be essential to the protective immune response in microMT mice because NK cell depletion with anti-asialo-GM1 antibody resulted in both the loss of tumor growth suppression and attenuation of the specific cellular immune response. The authors conclude that the protective cell-mediated immunity provoked by Ad-based cancer vaccines is enhanced in the absence of B cells, suggesting that a therapeutic regimen that includes depletion of B lymphocytes may be beneficial to cancer vaccine therapy.
Similar articles
- Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens.
Perricone MA, Claussen KA, Smith KA, Kaplan JM, Piraino S, Shankara S, Roberts BL. Perricone MA, et al. Mol Ther. 2000 Mar;1(3):275-84. doi: 10.1006/mthe.2000.0029. Mol Ther. 2000. PMID: 10933943 - Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Zhai Y, et al. J Immunother. 1997 Jan;20(1):15-25. doi: 10.1097/00002371-199701000-00002. J Immunother. 1997. PMID: 9101410 Free PMC article. - Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH. Tüting T, et al. J Gene Med. 1999 Nov-Dec;1(6):400-6. doi: 10.1002/(SICI)1521-2254(199911/12)1:6<400::AID-JGM68>3.0.CO;2-D. J Gene Med. 1999. PMID: 10753065 - Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D, Paschen A, Sun Y. Schadendorf D, et al. Immunol Lett. 2000 Sep 15;74(1):67-74. doi: 10.1016/s0165-2478(00)00251-0. Immunol Lett. 2000. PMID: 10996630 Review. - Therapeutic vaccines against melanoma and colorectal cancer.
Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Tartaglia J, et al. Vaccine. 2001 Mar 21;19(17-19):2571-5. doi: 10.1016/s0264-410x(00)00491-6. Vaccine. 2001. PMID: 11257394 Review.
Cited by
- B cells in head and neck squamous cell carcinoma: current opinion and novel therapy.
Guo X, Xu L, Nie L, Zhang C, Liu Y, Zhao R, Cao J, Tian L, Liu M. Guo X, et al. Cancer Cell Int. 2024 Jan 20;24(1):41. doi: 10.1186/s12935-024-03218-3. Cancer Cell Int. 2024. PMID: 38245714 Free PMC article. Review. - Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer.
Wang Z, Wang Q, Tao Y, Chen J, Yuan Z, Wang P. Wang Z, et al. Sci Data. 2023 Oct 12;10(1):694. doi: 10.1038/s41597-023-02611-3. Sci Data. 2023. PMID: 37828063 Free PMC article. - T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: First report from Upper Egypt.
Mohammed SA, Hetta HF, Zahran AM, Tolba MEM, Attia RAH, Behnsawy HM, Algammal AM, Batiha GE, Mohammed AQ, Ahmad AA. Mohammed SA, et al. PLoS Negl Trop Dis. 2023 Apr 17;17(4):e0011258. doi: 10.1371/journal.pntd.0011258. eCollection 2023 Apr. PLoS Negl Trop Dis. 2023. PMID: 37068081 Free PMC article. - B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma.
Minici C, Testoni S, Della-Torre E. Minici C, et al. Front Immunol. 2022 Mar 14;13:867902. doi: 10.3389/fimmu.2022.867902. eCollection 2022. Front Immunol. 2022. PMID: 35359944 Free PMC article. Review. - Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
Tousif S, Wang Y, Jackson J, Hough KP, Strenkowski JG, Athar M, Thannickal VJ, McCusker RH, Ponnazhagan S, Deshane JS. Tousif S, et al. Front Immunol. 2021 Nov 19;12:747780. doi: 10.3389/fimmu.2021.747780. eCollection 2021. Front Immunol. 2021. PMID: 34867973 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous